# Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

> **NCT00161590** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University**

## Conditions studied

- T-Cell Lymphoma
- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** CHOP and alemtuzumab

## Key facts

- **NCT ID:** NCT00161590
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161590, "Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00161590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*